Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Motyl

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Infectious Disease|May 17, 2021
Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiogramsKenneth P Klinker, Levita K Hidayat, C Andrew DeRyke, et al.
The Journal of Antibiotics|August 1, 2024
Antibacterial and mechanism of action studies of boxazomycin ASheo B Singh, James Occi, John Ondeyka, et al.
Antimicrobial Agents and Chemotherapy|December 15, 2020
Molecular Characterization of Baseline <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical TrialMariana Castanheira, Matthew G Johnson, Brian Yu, et al.
Emerging Infectious Diseases|May 19, 2018
Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014Gisele Peirano, Yasufumi Matsumura, Mark D Adams, et al.
Antibiotics (Basel, Switzerland)|May 28, 2022
Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United StatesKenneth P Klinker, Levita K Hidayat, Eric Wenzler, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2018
Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in QatarSaad J Taj-Aldeen, Husam Salah, Winder B Perez, et al.
International Journal of Antimicrobial Agents|January 12, 2021
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)Matthew G Johnson, Christopher Bruno, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2018
<i>In Vivo</i> Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection ModelsMary Ann Powles, Andrew Galgoci, Andrew Misura, et al.
Infectious Diseases and Therapy|June 12, 2016
In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance StudyDouglas J Biedenbach, Robert E Badal, Ming-Yi Huang, et al.
Infectious Diseases and Therapy|July 18, 2016
Erratum to: In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance StudyDouglas J Biedenbach, Robert E Badal, Ming-Yi Huang, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Infectious Disease|May 17, 2021
Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiogramsKenneth P Klinker, Levita K Hidayat, C Andrew DeRyke, et al.
The Journal of Antibiotics|August 1, 2024
Antibacterial and mechanism of action studies of boxazomycin ASheo B Singh, James Occi, John Ondeyka, et al.
Antimicrobial Agents and Chemotherapy|December 15, 2020
Molecular Characterization of Baseline <i>Enterobacterales</i> and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical TrialMariana Castanheira, Matthew G Johnson, Brian Yu, et al.
Emerging Infectious Diseases|May 19, 2018
Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014Gisele Peirano, Yasufumi Matsumura, Mark D Adams, et al.
Antibiotics (Basel, Switzerland)|May 28, 2022
Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United StatesKenneth P Klinker, Levita K Hidayat, Eric Wenzler, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2018
Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in QatarSaad J Taj-Aldeen, Husam Salah, Winder B Perez, et al.
International Journal of Antimicrobial Agents|January 12, 2021
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)Matthew G Johnson, Christopher Bruno, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|June 6, 2018
<i>In Vivo</i> Efficacy of Relebactam (MK-7655) in Combination with Imipenem-Cilastatin in Murine Infection ModelsMary Ann Powles, Andrew Galgoci, Andrew Misura, et al.
Infectious Diseases and Therapy|June 12, 2016
In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance StudyDouglas J Biedenbach, Robert E Badal, Ming-Yi Huang, et al.
Infectious Diseases and Therapy|July 18, 2016
Erratum to: In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance StudyDouglas J Biedenbach, Robert E Badal, Ming-Yi Huang, et al.
Pageof 5